Lymphoma, Large B-Cell, Diffuse Clinical Trial
Official title:
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
Mindsets are lenses or frames of mind that orient individuals to a particular set of
expectations and associations. This study aims to leverage specific and empirically supported
mindsets (i.e., 'cancer is manageable' and 'the body is capable') to reduce distress and
improve physical health and psychological wellbeing in patients with cancer being treated
with curative intent. This intervention will take the form of several brief documentary style
film segments which feature both cancer survivors and experts in the fields of Oncology,
Psychology, and Psychiatry.
Although no mindset-targeted interventions have been studied in cancer patients to date,
other psychosocial interventions have demonstrated efficacy in treating emotional distress
and improving quality of life in this population. However, compared with these standard
interventions, mindset interventions need not be lengthy, complex, or costly to yield major
effects. Thus, this project aims to lay the groundwork for future scalable and efficient
interventions that can meaningfully reduce distress and improve health and wellbeing in this
population.
A diagnosis of cancer causes significant emotional distress in a substantial proportion of
patients. This distress impacts physical and mental health outcomes and often goes
unrecognized and untreated. Psychosocial interventions have been proven effective in
ameliorating cancer related distress. While the literature supports the use of standard
psychosocial interventions like Mindfulness Based Stress Reduction (MBSR) and Cognitive
Behavioral Therapy (CBT) for cancer patients, effects are typically only found in
interventions lasting longer than 12 weeks. This constraint represents a considerable time
commitment on the part of the patient and large financial commitment on the part of the
healthcare system. As such, there is a need for brief, scalable, cost-effective interventions
that are informed by psychological theory but do not require access to trained mental health
professionals and could potentially be delivered by oncology clinicians during cancer
treatment without specialized referrals. This may also facilitate better comprehensive care
for patients without insurance covering mental health services.
Interventions that target mindsets may be well suited to fill this need. A mindset is a lens
or frame of mind that orients an individual to a particular set of associations and
expectations. Mindsets may serve as an important psychosocial variable that can be leveraged
to improve health outcomes. The impact of mindsets has been documented extensively in the
context of stress, diet, and exercise. Mindsets also likely play a large role in shaping
other clinical outcomes including blood pressure and hormone response as well. Because
mindset interventions target specific mindsets rather than more general cognitive or
affective processes, they can effectively shape downstream targets like attention,
motivation, affect, and physiology despite their apparent brevity.
Mindsets in clinical populations have been relatively understudied. However, preliminary
findings indicate that mindsets about the body, illness, and medications are significantly
related to critical health outcomes and quality of life in individuals with chronic illness.
For instance, patients with cancer who endorsed the mindset that cancer is a catastrophe
reported lower levels of physical and social functioning, worse quality of life, and poorer
perceived health. Conversely, patients who adopted the mindset that cancer is manageable or
the mindset that cancer can be an opportunity to make important life changes or pursue goals
reported better physical functioning, social functioning, perceived health, and quality of
life.
This study aims to understand patient mindsets and quantify the impact of a highly targeted
mindset intervention in a diverse population of patients with cancer. The investigators
hypothesize that mindsets will also impact treatment efficacy, reporting and management of
adverse events, physiological markers of health and disease, global functioning, quality of
life, and fear of recurrence in individuals diagnosed with cancer and treated with curative
intent.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03977623 -
Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
|
||
Recruiting |
NCT02428751 -
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
|
Phase 3 | |
Completed |
NCT02555267 -
Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT02364050 -
Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM
|
||
Terminated |
NCT00529503 -
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
|
Phase 2 | |
Terminated |
NCT02413489 -
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
|
Phase 2 | |
Completed |
NCT02086604 -
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
Phase 1 | |
Completed |
NCT01421524 -
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT03600363 -
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
|
Phase 2 | |
Recruiting |
NCT03646422 -
AEDV Registry of Primary Cutaneous Lymphoma
|
||
Recruiting |
NCT04446962 -
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03241017 -
Durvalumab in DLBCL After Autologous Transplant
|
Phase 2 | |
Recruiting |
NCT02931201 -
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma
|
N/A | |
Recruiting |
NCT02928861 -
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
|
N/A | |
Terminated |
NCT02592876 -
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
Completed |
NCT00849147 -
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
|
Phase 2 | |
Completed |
NCT00822432 -
Coproporphyrine Isomers and Methotrexate Elimination
|
N/A | |
Completed |
NCT03682796 -
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04982471 -
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
|
||
Completed |
NCT03744676 -
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
|
Phase 2 |